Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status (1 selected)

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 91 to 105 of 139 results for chronic heart failure

  1. Early and locally advanced breast cancer: diagnosis and management (NG101)

    This guideline covers diagnosing and managing early and locally advanced breast cancer. It aims to help healthcare professionals offer the right treatments to people, taking into account the person's individual preferences.

  2. Benralizumab for treating relapsing or refractory eosinophilic granulomatosis with polyangiitis (TA1096)

    Evidence-based recommendations on benralizumab (Fasenra) for treating relapsing or refractory eosinophilic granulomatosis with polyangiitis in adults.

  3. Exagamglogene autotemcel for treating severe sickle cell disease in people 12 years and over (TA1044)

    Evidence-based recommendations on exagamglogene autotemcel (Casgevy) for treating severe sickle cell disease in people 12 years and over.

  4. Avalglucosidase alfa for treating Pompe disease (TA821)

    Evidence-based recommendations on avalglucosidase alfa (Nexviadyme) for Pompe disease.

  5. Pixantrone monotherapy for treating multiply relapsed or refractory aggressive non-Hodgkin's B‑cell lymphoma (TA306)

    Evidence-based recommendations on pixantrone (Pixuvri) for treating relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma in adults.

  6. i STAT CG4+ and CHEM8+ cartridges for point-of-care testing in the emergency department (MIB38)

    NICE has developed a medtech innovation briefing (MIB) on i STAT CG4+ and CHEM8+ cartridges for point-of-care testing in the emergency department

  7. Sternal Talon for sternal closure in cardiothoracic surgery (MIB88)

    NICE has developed a medtech innovation briefing (MIB) on the Sternal Talon for sternal closure in cardiothoracic surgery .

  8. Cough (acute): antimicrobial prescribing (NG120)

    This guideline sets out an antimicrobial prescribing strategy for acute cough associated with an upper respiratory tract infection or acute bronchitis in adults, young people and children. It aims to limit antibiotic use and reduce antibiotic resistance.

  9. Procalcitonin testing for diagnosing and monitoring sepsis (ADVIA Centaur BRAHMS PCT assay, BRAHMS PCT Sensitive Kryptor assay, Elecsys BRAHMS PCT assay, LIAISON BRAHMS PCT assay and VIDAS BRAHMS PCT assay) (HTG386)

    Evidence-based recommendations on procalcitonin testing for diagnosing and monitoring sepsis (ADVIA Centaur BRAHMS PCT assay, BRAHMS PCT Sensitive Kryptor assay, Elecsys BRAHMS PCT assay, LIAISON BRAHMS PCT assay and VIDAS BRAHMS PCT assay).

  10. Eating disorders: recognition and treatment (NG69)

    This guideline covers assessment, treatment, monitoring and inpatient care for children, young people and adults with eating disorders. It aims to improve the care people receive by detailing the most effective treatments for anorexia nervosa, binge eating disorder and bulimia nervosa.

  11. Ustekinumab for treating active psoriatic arthritis (TA340)

    Evidence-based recommendations on ustekinumab (Stelara) for treating active psoriatic arthritis in adults.

  12. Implantable cardiac monitors to detect atrial fibrillation after cryptogenic stroke (HTG553)

    Evidence-based recommendations on implantable cardiac monitors to detect atrial fibrillation after cryptogenic stroke.

  13. Exagamglogene autotemcel for treating transfusion-dependent beta-thalassaemia in people 12 years and over (TA1003)

    Evidence-based recommendations on exagamglogene autotemcel (Casgevy) for transfusion-dependent beta-thalassaemia in people 12 years and over.

  14. Lumasiran for treating primary hyperoxaluria type 1 (HST25)

    Evidence-based recommendations on lumasiran (Oxlumo) for primary hyperoxaluria type 1 in people of all ages.

  15. Imlifidase for desensitisation treatment before kidney transplant in people with chronic kidney disease (TA809)

    Evidence-based recommendations on imlifidase (Idefirix) for desensitisation treatment before kidney transplant in people with chronic kidney disease.